United States securities and exchange commission logo





                             April 21, 2022

       Richard Garr
       Chief Executive Officer
       Curative Biotechnology, Inc.
       1825 NW Corporate Blvd, Suite 110
       Boca Raton, FL 33431

                                                        Re: Curative
Biotechnology, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed April 15,
2022
                                                            File No. 333-264339

       Dear Mr. Garr:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1 filed April 15, 2022

       Statements of Operations, page F-5

   1.                                                   We note that you
revised the Statement of Operations for the year ended December 31,
                                                        2020 to include the
impairment of long-lived assets of $32,136 and to revise the net loss
                                                        amount back to
$4,670,255. Accordingly, please revise the net loss amounts disclosed in
                                                        the Risk Factors
section on pages 7 and 8 from $4,638,119 to $4,670,255.
       General

   2.                                                   Please identify the
lender(s) under the secured convertible promissory note dated March 4,
                                                        2022 in your
disclosure, where discussed.
 Richard Garr
FirstName   LastNameRichard
Curative Biotechnology, Inc. Garr
Comapany
April       NameCurative Biotechnology, Inc.
       21, 2022
April 221, 2022 Page 2
Page
FirstName LastName
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

        You may contact Jeanne Bennett at 202-551-3606 or Vanessa Robertson at
202-551-3649
if you have questions regarding comments on the financial statements and
related
matters. Please contact Jason Drory at 202-551-3649 or Laura Crotty at
202-551-7614 with any
other questions.



                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:      Raul Silvestre, Esq.